Impact of cancer therapies on ovarian reserve - Wikidata - thesis-toulmin - TriplyDB

Impact of cancer therapies on ovarian reserve

Impact of cancer therapies on ovarian reserve

http://www.wikidata.org/entity/Q28384958

about

The Bologna criteria for poor ovarian response: a contemporary critical appraisal Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review Quantification of anti-Müllerian hormone (AMH) in dried blood spots: validation of a minimally invasive method for assessing ovarian reserve Pregnancy after cancer: results from a prospective cohort study of cancer survivors Self-collected dried blood spots as a tool for measuring ovarian reserve in young female cancer survivors Cosmetics use and age at menopause: is there a connection?Acute exposure to high dose γ-radiation results in transient activation of bone lining cells Current state and controversies in fertility preservation in women with breast cancer.Fertility preservation outcomes may differ by cancer diagnosis.A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer.The physiology and clinical utility of anti-Mullerian hormone in women.Sexual dysfunction and infertility as late effects of cancer treatment.Challenges and considerations in optimizing ovarian stimulation protocols in oncofertility patients.Pubertal development and primary ovarian insufficiency in female survivors of embryonal brain tumors following risk-adapted craniospinal irradiation and adjuvant chemotherapy.Outcomes of ovarian stimulation after treatment with chemotherapy Dynamics of the ovarian reserve and impact of genetic and epidemiological factors on age of menopause.Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer Oncofertility: a grand collaboration between reproductive medicine and oncology Hypothyroidism after cancer and the ability to meet reproductive goals among a cohort of young adult female cancer survivors.Embryo banking among women diagnosed with cancer: a pilot population-based study in New York, Texas, and Illinois.Effects of gamma radiation on fetal development in mice.Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice.Anti-Müllerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies.Quality of life in female cancer survivors: is it related to ovarian reserve?Fertility preservation options after gonadotoxic chemotherapy Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review.Fertility preservation in the female cancer patient.Infertility in reproductive-age female cancer survivors.Chemotherapy-induced damage to ovary: mechanisms and clinical impact.Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration W Which female cancer patients fail to receive fertility counseling before treatment in the state of Georgia?Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles.The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels.The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.Ovarian function after chemotherapy in young breast cancer survivors.Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

P2860

Q27021821-4B581B23-F8FD-404C-8120-31C80ADD3F7C Q28240178-0CC89B85-CEF3-48FD-ACD1-2144740D74A5 Q28383325-6BA0CC45-6740-43AB-91BF-108603D7CD04 Q28384104-D6AE2356-9500-4323-B4DF-5B9C9A92FA69 Q28386434-1634B9CA-A8AB-4EA3-B7EC-FB0B0C8C6D75 Q28395757-6982B0E6-F2E7-4852-B4E1-7BA3EC2533AA Q28396648-9292554E-1434-44A2-9BF7-233A4B8BDBCE Q30248371-994B7421-A5AC-4D2B-A573-1290CCCC1968 Q33702479-72CEB9D9-F3D4-404D-AEBB-8E343BDD94BC Q33779879-75818B48-7D46-4F56-9623-2A26123C7485 Q34112999-0D4861C2-8E6A-426A-976D-5F010042AEEB Q34199333-09C93D94-9EA0-442F-B16D-31FFAC0C855B Q34398233-7C06D016-15B8-44E2-B5B5-C88AB36A3289 Q34604454-A5298F84-8A71-4447-B2CF-2ED1138656BF Q34637134-B837D922-30E5-4F8E-B4E1-65E0AA7A5C96 Q35469749-C298B377-0C88-4969-B816-0A00A8B10190 Q36192069-AFF7191B-F19A-4F55-9ABE-05AEBE2F88C0 Q36282786-1619B9AA-93FF-4273-92A5-0F5A7BCA8618 Q36370462-F056E8B5-C7AB-45BC-BC3F-2981A08DD56D Q36405648-25DDFD58-8FDE-4CC2-A8D4-4A165FB4E7C8 Q36455946-AFFAE31F-2257-4E98-AFA9-E10E40201D6B Q36456034-F249049A-8A35-4CCA-8967-739C4DCA9B97 Q36910180-269F9DA5-F6A1-424E-8816-F47D5CA25C3A Q37032904-D830DCDC-BEE2-44BC-8AE5-F5115F6FBBA3 Q37253591-63C3EF8F-9ACA-4FD8-826E-E3B78F8AAEDA Q37400331-9E09C578-83ED-4A1A-9A82-8467D2977322 Q37404397-1B6C00B2-D97C-40C3-8D72-BF16E4F68D06 Q37413518-F89AA7C9-7377-4953-A452-60B75A704E90 Q37463079-CD68123C-CA3C-4250-A487-2C3CA5EB88D2 Q38250303-9BC8C7B7-C86D-4E37-95DC-C902605A787A Q38256884-1083FBBF-FB9C-4708-9578-FB39ADA45FA7 Q38343285-7A72A633-48F8-4687-8AE2-5644329333A5 Q38842887-95F0407E-0752-414B-A919-BCFE667CC1D1 Q38908606-EFD47593-7965-4C9D-9969-1FDABC4ECC61 Q40563442-5E4081CF-F4FB-4D10-B072-8160DA661D99 Q40566569-5821A484-5DF9-4E93-BDF3-0E2F45F7A3E0 Q44308980-EA54D3E0-46BB-4F3D-AC50-24B1A89D363D Q47097531-60439018-9C1A-48C5-9758-C4B1C6F94796 Q47124589-032DAE07-8047-485A-B714-0C63CA445E36 Q47170320-1A42B2CB-4AA4-4410-94DA-C58BE8C364FC

P2860

Impact of cancer therapies on ovarian reserve

http://www.wikidata.org/entity/Q28384958

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Impact of cancer therapies on ovarian reserve

@ast

Impact of cancer therapies on ovarian reserve

@en

Impact of cancer therapies on ovarian reserve

@nl

type

label

Impact of cancer therapies on ovarian reserve

@ast

Impact of cancer therapies on ovarian reserve

@en

Impact of cancer therapies on ovarian reserve

@nl

prefLabel

Impact of cancer therapies on ovarian reserve

@ast

Impact of cancer therapies on ovarian reserve

@en

Impact of cancer therapies on ovarian reserve

@nl

P1433

Q28384958-874614ED-BA8D-4C06-9586-A5BBC0617A8A

P1476

Q28384958-D128C485-FEC5-48A0-8D45-E43950245EB6

P2093

Q28384958-05D9718A-EB2B-4137-A183-B018B4A16A03

Q28384958-209C7356-C2D5-449F-AF5A-3D429168095A

Q28384958-578635AC-4D70-4FFF-88A3-F23DC2D22438

Q28384958-C85B8787-AD4B-4702-BCB8-497A3B6F489E

Q28384958-CF560085-45C6-4DD6-A4D3-D81D11B87919

Q28384958-EA807B59-673F-4DB8-ABD2-3E67A18226E8

Q28384958-F061AFBC-F3CF-4B8B-8862-AC9B8D9EF24F

Q28384958-F6EEF44D-CDCC-49DE-8280-5DA599683586

P2860

Q28384958-007ABE8E-66D2-4526-B9C9-E7D32F1FCE0A

Q28384958-03C568C6-4564-44B3-8A67-5AEB74D6FFCF

Q28384958-10756AC1-BEB6-45CD-AF26-7B6A2A2D39E6

Q28384958-13CF6CD3-7C28-4EDA-BC1D-448F1A65732C

Q28384958-217E4711-2DD1-4489-ADD8-FF3DDA6D87B8

Q28384958-271DEAFD-54E4-4BED-AE75-38A18F638F16

Q28384958-33E5F9F3-77CF-4950-9C5D-E2F5E5114E6E

Q28384958-46138782-69C7-428D-BA48-B3CDD3239491

Q28384958-58467DC6-9D07-4370-B93D-9B2818FF4969

Q28384958-62B73312-880C-4439-B733-3E8F2E0434A6

P304

Q28384958-C2E77B8D-3EF0-4E79-B7CD-D25DDBA6BBDE

P31

Q28384958-64658030-0A7C-4E58-9B9B-964E0EFEDFAB

P3181

Q28384958-BB73C9F9-EA83-48EA-B6F5-6E5F32D4D065

P356

Q28384958-5A6ACEC4-4FEB-460F-A192-EC623FD53651

P407

Q28384958-D55CDA32-5654-426D-8F28-8A584C65C10A

P433

Q28384958-DB4AE622-AEBC-44EA-B966-06B98045AACF

P478

Q28384958-FF06968A-1D83-43AC-A157-038DB8499B5B

P577

Q28384958-9C458C88-0E37-4F42-8644-8953D2A9F695

P698

Q28384958-FCF1DD72-2391-47F6-AE52-B66C685DEEC1

P921

Q28384958-B4EEEADE-5FD1-4AB9-B5F6-E03454CBE27A

P932

Q28384958-886F814E-BC41-45B6-9FFA-0E62496041EC

P3181

P356

J.FERTNSTERT.2011.10.040

P1433

Fertility and Sterility

P1476

Impact of cancer therapies on ovarian reserve

@en

P2093

Anushree Ray

http://www.w3.org/2001/XMLSchema#string

Ashley Vance

http://www.w3.org/2001/XMLSchema#string

Claire Carlson

http://www.w3.org/2001/XMLSchema#string

Clarisa R Gracia

http://www.w3.org/2001/XMLSchema#string

Ellen Freeman

http://www.w3.org/2001/XMLSchema#string

Jill P Ginsberg

http://www.w3.org/2001/XMLSchema#string

Mary D Sammel

http://www.w3.org/2001/XMLSchema#string

Maureen Prewitt

http://www.w3.org/2001/XMLSchema#string

P2860

Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years

Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study.

Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors: a review.

Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study.

Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation.

Symptoms associated with menopausal transition and reproductive hormones in midlife women.

Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition.

Childhood cancer: fertility and psychosocial implications.

Toxicity of chemotherapy and radiation on female reproduction.

Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases.

P304

134-40.e1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4258456

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.FERTNSTERT.2011.10.040

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22137491

http://www.w3.org/2001/XMLSchema#string

P921

reproductive medicine

P932

4005036

http://www.w3.org/2001/XMLSchema#string